TradeFlare's AI research teams analysed MBX on 11 market nights between May 25, 2026 and August 31, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 31, 2026 | HOLD | $63.00 | — / — | +2.3% | -6.2% | Positive clinical trial data for canvuparatide and obesity pipeline. |
| June 24, 2026 | BUY | $46.39 | $57.52 / $39.43 | +15.5% | +31.3% | The post-earnings drift suggests continued upward momentum over the coming weeks. |
| June 23, 2026 | BUY Published signal · reached target +24.4% |
$43.91 | $52.69 / $37.32 | +19.0% | +25.7% | The post-earnings drift signal suggests a short-term upward momentum. |
| June 22, 2026 | BUY | $43.03 | $51.64 / $36.58 | +22.6% | +37.3% | The post-earnings drift pattern suggests momentum could persist for several weeks. |
| June 18, 2026 | BUY | $41.59 | $49.91 / $35.35 | +21.6% | +39.8% | The post-earnings drift signal suggests a sustained upward move over the coming weeks. |
| June 17, 2026 | BUY | $40.09 | — / — | +21.1% | +51.3% | Positive clinical trial data for canvuparatide. |
| May 29, 2026 | BUY | $31.90 | $37.80 / $26.78 | -3.8% | +71.1% | The setup suggests a potential short-term bounce driven by technical oversold conditions and fundamental bullishness, but the high risk profile necessitates a shorter time horizon. |
| May 28, 2026 | BUY | $31.88 | — / — | -3.1% | +64.0% | Successful progression of MBX's peptide therapeutics pipeline through clinical trials. |
| May 27, 2026 | BUY | $31.75 | — / — | -5.7% | +58.0% | The scanner triggered a short-term mean-reversion signal, but the overall market and stock technicals are neutral. |
| May 26, 2026 | BUY | $31.85 | — / — | -3.3% | +52.4% | The current market and stock conditions suggest a period of consolidation and observation is warranted before committing capital. |
| May 25, 2026 | BUY | $31.85 | — / — | -3.3% | +52.4% | The stock is in a neutral market regime and while fundamentals are bullish, technicals are neutral and risk is high, requiring a clearer technical setup or catalyst. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.